Affymax to dissolve company

Thursday, June 26, 2014

The board of directors of biopharmaceutical company Affymax has approved the liquidation and dissolution of the company, subject to stockholder approval, and plans to distribute all available cash to its stockholders.

[Read More]

Affymax cuts 75% of employees in midst of ongoing product investigation

Tuesday, March 19, 2013

Palo Alto, Calif.-based Affymax will reduce its workforce as part of a plan to focus the company’s resources on the ongoing investigation of reported hypersensitivity reactions in patients receiving Omontys injection following the nationwide voluntary recall of the product from the market. Approximately 230 employees (or 75%) will be cut, including its commercial and medical affairs field organizations and other officers and employees.

[Read More]